Proton therapy for hepatocellular carcinoma: Current knowledges and future perspectives

World J Gastroenterol. 2018 Jul 28;24(28):3090-3100. doi: 10.3748/wjg.v24.i28.3090.

Abstract

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death, as few patients can be treated with currently available curative local modalities. In patients with HCC where curative modalities are not feasible, radiation therapy (RT) has emerged as an alternative or combination therapy. With the development of various technologies, RT has been increasingly used for the management of HCC. Among these advances, proton beam therapy (PBT) has several unique physical properties that give it a finite range in a distal direction, and thus no exit dose along the beam path. Therefore, PBT has dosimetric advantages compared with X-ray therapy for the treatment of HCC. Indeed, various reports in the literature have described the favorable clinical outcomes and improved safety of PBT for HCC patients compared with X-ray therapy. However, there are some technical issues regarding the use of PBT in HCC, including uncertainty of organ motion and inaccuracy during calculation of tissue density and beam range, all of which may reduce the robustness of a PBT treatment plan. In this review, we discuss the physical properties, current clinical data, technical issues, and future perspectives on PBT for the treatment of HCC.

Keywords: Hepatocellular carcinoma; Proton beam therapy; Radiation therapy; X-ray therapy.

Publication types

  • Review

MeSH terms

  • Carcinoma, Hepatocellular / radiotherapy*
  • DNA Damage / radiation effects
  • Digestive System / radiation effects*
  • Humans
  • Liver Neoplasms / radiotherapy*
  • Proton Therapy / adverse effects
  • Proton Therapy / methods
  • Proton Therapy / statistics & numerical data*
  • Proton Therapy / trends
  • Radiation Injuries / etiology
  • Radiometry
  • Radiotherapy Dosage
  • Treatment Outcome